QLT Begins Dosing In Phase 2 Trial Of QLT091001 For Impaired Dark Adaptation

(RTTNews) - QLT Inc. (QLTI, QLT.TO), Monday said it dosed the first patient in its Phase IIa proof-of-concept trial of QLT091001 in adults with Impaired Dark Adaptation or IDA, a condition that results in decreased ability to recover visual sensitivity in the dark after exposure to bright lights. The study will evaluate the safety profile and effects of QLT091001 on impaired dark adaptation time, glare recovery time and low luminance low contrast best corrected visual acuity or LLLC BCVA.

The trial is demonstrated in subjects with IDA, or impaired LLLC BCVA in at least one eye and having no known ophthalmic pathologies to explain their condition other than early age-related macular degeneration in the U.S.

"This is an important step outside of rare orphan diseases with QLT091001, one which is designed to illustrate its potential in a significantly larger patient population." aid Mr. Jason Aryeh, Chairman of the Board.